JPH05246822A - Antibacterial agent - Google Patents

Antibacterial agent

Info

Publication number
JPH05246822A
JPH05246822A JP8468692A JP8468692A JPH05246822A JP H05246822 A JPH05246822 A JP H05246822A JP 8468692 A JP8468692 A JP 8468692A JP 8468692 A JP8468692 A JP 8468692A JP H05246822 A JPH05246822 A JP H05246822A
Authority
JP
Japan
Prior art keywords
acid
antibacterial agent
affected part
propionibacterium acnes
usnic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8468692A
Other languages
Japanese (ja)
Inventor
Masako Higuchi
允子 樋口
Yasutaka Miura
靖高 三浦
Yasuhiro Kinoshita
靖浩 木下
Yoshikazu Yamamoto
好和 山本
Shigeyuki Mayama
滋志 真山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Paint Co Ltd
Original Assignee
Nippon Paint Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Paint Co Ltd filed Critical Nippon Paint Co Ltd
Priority to JP8468692A priority Critical patent/JPH05246822A/en
Publication of JPH05246822A publication Critical patent/JPH05246822A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

PURPOSE:To obtain an antibacterial agent usable as cosmetic or medicine for preventing and treating microbism (pimple) with Propionibacterium acnes, having excellent stability. CONSTITUTION:An antibacterial agent against Propionibacterium acnes, containing usnic acids such as usnic acid, isousnic acid, didymic acid, placodiolic acid, pannaric acid, schizopeltic acid, strepsilin and polyphyllic acid or lichesterinic acids such as lichesterinic acid, protolichesterinic acid, nephrosterinic acid, acarenoic acid, acaranoic acid, nephrosteranic acid, nephromopsic acid and roccellaric acid as an active ingredient. Generally the antibacterial agent is directly applied to the affected part by external method and may be orally administered. A dose is varied depending upon the area of the affected part, etc., and, for example, a dose containing 0.001-10% active ingredient is thinly applied to the affected part several times daily.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、プロピオニバクテリウ
ム・アクネスによる皮膚細菌感染症の防止、治療のため
の化粧品、感染症治療のための医薬品等の分野で利用可
能な抗菌剤及びその製造法に関するものである。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an antibacterial agent which can be used in the fields of cosmetics for preventing and treating skin bacterial infections caused by Propionibacterium acnes, pharmaceuticals for treating infectious diseases, and the production thereof. It is about law.

【0002】[0002]

【従来の技術】皮膚疾患の一つであるニキビの原因は種
々想定されているが、ホルモン活性の増加により皮脂の
分泌がさかんとなり、その皮脂が毛嚢皮脂線に充満、閉
塞して嫌気雰囲気を作り上げた結果、皮膚毛嚢内に常在
する嫌気性のグラム陽性細菌の一種であるプロピオニバ
クテリウム・アクネスが異常繁殖して引き起こすもので
あると考えられている。
Background Art Although various causes of acne, which is one of the skin diseases, are supposed, the secretion of sebum is increased due to the increase of hormonal activity, and the sebum is filled and sequestered in the hair follicle sebaceous line to cause an anaerobic atmosphere. As a result, it is considered that Propionibacterium acnes, which is a kind of anaerobic Gram-positive bacterium that is resident in the hair follicles, is caused by abnormal breeding.

【0003】一方、ウスニン酸やリケステリン酸は地衣
類固有の代謝産物いわゆる地衣成分として知られている
化合物群に含まれる。地衣類はある種の菌類と藻類から
成り立っている共生体であって、植物学的にも、特異な
地位を占める一群の植物である。地衣成分は具体的には
朝比奈らにより分類されている(朝比奈・柴田著「地衣成
分の化学」河出書房(1948年))。
On the other hand, usnic acid and liquesteric acid are included in a group of compounds known as lichen-specific metabolites, so-called lichen components. Lichens are symbionts consisting of certain fungi and algae, and are a group of plants that occupy a unique position botanically. Lichen components are specifically classified by Asahina et al. (Asahina and Shibata, "Chemistry of Lichen Components", Kawade Shobo (1948)).

【0004】地衣成分の生理学的意義については、地衣
類の生育が緩慢であることから、微生物の攻撃や小動物
の喰害に対する防御であるとか、また他の菌類とは異な
り日向に生育することから紫外線に対する防御であると
か考えられている。そのため古来から地衣成分はこれら
機能から生じた用途に使用されてきた。しかし、これら
地衣成分の薬理作用についてはほとんど検討されていな
い。
Regarding the physiological significance of the lichen component, since the growth of lichen is slow, it is a defense against microbial attack and feeding of small animals, and unlike other fungi, it grows in the sun. It is considered to be protection against ultraviolet rays. Therefore, since ancient times, lichen components have been used for applications resulting from these functions. However, the pharmacological actions of these lichen components have been scarcely studied.

【0005】[0005]

【発明が解決しようとする課題】サルファ剤や抗生物質
がプロピオニバクテリウム・アクネスによるニキビの治
療剤として利用されているが、当該菌の抵抗性獲得によ
る殺菌効果あるいは増殖抑制効果の低下が顕著になって
きている。一方、病原菌による感染症に対する治療薬の
多くは投薬上安全性の観点から副作用等の点で問題があ
り、常に新たな治療薬を探索していく必要がある。
[Problems to be Solved by the Invention] Sulfa drugs and antibiotics are used as therapeutic agents for acne caused by Propionibacterium acnes, but the bactericidal effect or growth inhibitory effect due to the acquired resistance of the bacteria is markedly reduced. It has become to. On the other hand, many therapeutic agents for infectious diseases caused by pathogenic bacteria have problems in terms of side effects and the like from the viewpoint of drug safety, and it is necessary to constantly search for new therapeutic agents.

【0006】本発明の目的はニキビ原因菌の一つである
プロピオニバクテリウム・アクネスに対する抗菌剤を提
供することにある。
An object of the present invention is to provide an antibacterial agent against Propionibacterium acnes which is one of acne-causing bacteria.

【0007】[0007]

【課題を解決するための手段】本発明が提供することに
成功したプロピオニバクテリウム・アクネスに対する抗
菌剤は、ウスニン酸類またはリケステリン酸類を有効成
分として含有することを特徴とするものである。
The antibacterial agent against Propionibacterium acnes successfully provided by the present invention is characterized by containing usnic acid or liquesteric acid as an active ingredient.

【0008】本発明に係わる有効成分であるウスニン酸
類はジベンゾフラン系の化合物群を広く意味し、ウスニ
ン酸(1)、イソウスニン酸(2)、ジジム酸(3)、プラコ
ジオール酸、パンナ酸、シゾペルツ酸、ストレプシリ
ン、ポリフィリン酸等が挙げられる。
Usnic acid, which is an active ingredient according to the present invention, broadly means a group of dibenzofuran compounds, and is usnic acid (1), isousnic acid (2), didimic acid (3), prakodiolic acid, pannaic acid, cizopertuic acid. , Strepcillin, porphyrinic acid and the like.

【0009】これらの製法は公知であるが、例えばJ.A.
Elix & A'.A.Whiton Progr. Chem.Organ.Nat.Prod.45,
103-234(1984年)に記載された方法により製造される。
Although these manufacturing methods are known, for example, JA
Elix &A'.A.Whiton Progr. Chem.Organ.Nat.Prod.45,
It is manufactured by the method described in 103-234 (1984).

【0010】また、リケステリン酸類は脂肪酸ラクトン
系の化合物群を広く意味し、リケステリン酸(4)、プロ
トリケステリン酸(5)、ネフロステリン酸(6)、アカレ
ン酸、アカラン酸、ネフロステラン酸、ネフロモプシン
酸、ロクセラ酸等が挙げられる。
Further, liquesteric acids broadly mean a group of fatty acid lactone compounds, and include liquesteric acid (4), protricesteric acid (5), nefosteric acid (6), acalenic acid, acaranic acid, nephrosteranic acid, neflomopsinic acid. , Roxeric acid and the like.

【0011】これらの製法も公知であるが、例えば朝比
奈・柴田著「地衣成分の化学」p17〜19に記載されて方法
により製造される。
Although these production methods are also known, for example, they are produced by the method described in "Chemistry of Lichen Components", pages 17 to 19 by Asahina and Shibata.

【0012】本発明の抗菌剤の投与方法は患部に直接塗
布する外用的用法が一般的であるが、経口投与してもよ
い。外用剤は溶液、乳液、軟膏として用いられる。ま
た、本発明の抗菌剤を他の組成物(例えば、化粧料)に加
えて使用してもよい。
The antibacterial agent of the present invention is generally administered externally by direct application to the affected area, but it may be orally administered. The external preparation is used as a solution, emulsion or ointment. In addition, the antibacterial agent of the present invention may be used in addition to other compositions (for example, cosmetics).

【0013】本発明の抗菌剤の投与量は患部面積、その
他の要因で大きく変化するが、例えば有効成分を0.0
01〜10%含むものを1日数回患部にうすく塗布す
る。
The dose of the antibacterial agent of the present invention varies greatly depending on the affected area and other factors.
Those containing 01 to 10% are thinly applied to the affected area several times a day.

【0014】[0014]

【発明の効果】ウスニン酸類、リケステリン酸類は、極
めて安定であり、プロピオニバクテリウム・アクネスに
起因するニキビの防止、治療のための化粧品に利用用可
能な極めて有用なものである。
INDUSTRIAL APPLICABILITY Usnic acids and liquesteric acids are extremely stable and extremely useful for cosmetics for the prevention and treatment of acne caused by Propionibacterium acnes.

【0015】[0015]

【実施例】以下に実施例を示すが、本発明はこれら実施
例に限定されない。
EXAMPLES Examples will be shown below, but the present invention is not limited to these examples.

【0016】(実施例)表1に示す地衣成分をアセトンに
溶解し、10-6g/ml溶液を作製した。50μlのアセト
ン溶液を染み込ませた濾紙ディスク(径8mm)を、予めプ
ロピオバクテリウム・アクネスを播種した寒天平板(径
90mm)上に同一サンプルにつき2枚づつ置き、37℃
で48時間嫌気培養し、その阻止円の大きさで抗菌活性
を測定した。
(Example) The lichen components shown in Table 1 were dissolved in acetone to prepare a 10 -6 g / ml solution. Place two filter paper discs (diameter 8 mm) soaked with 50 μl of acetone solution on the agar plate (diameter 90 mm) seeded with Propiobacterium acnes in duplicate for each sample and 37 ° C.
Anaerobic culture was carried out for 48 hours, and the antibacterial activity was measured by the size of the inhibition circle.

【0017】 [0017]

フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 C07D 307/91 (72)発明者 山本 好和 大阪府寝屋川市池田中町19番17号 日本ペ イント株式会社内 (72)発明者 真山 滋志 兵庫県西宮市枝川町17−2−243Front page continuation (51) Int.Cl. 5 Identification number Reference number within the agency FI Technical indication location C07D 307/91 (72) Inventor Yoshikazu Yamamoto 19-17 Ikedanaka-cho, Neyagawa-shi, Osaka Japan Paint Co., Ltd. (72) Inventor Shigeru Mayama 17-2-243 Edagawa-cho, Nishinomiya-shi, Hyogo

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 ウスニン酸類またはリケステリン酸類を
含有することを特徴とするプロピオニバクテリウム・ア
クネス(Propionibacterium acnes)に対する抗菌剤。
1. An antibacterial agent against Propionibacterium acnes, which contains usnic acid or liquesteric acid.
JP8468692A 1992-03-07 1992-03-07 Antibacterial agent Pending JPH05246822A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8468692A JPH05246822A (en) 1992-03-07 1992-03-07 Antibacterial agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8468692A JPH05246822A (en) 1992-03-07 1992-03-07 Antibacterial agent

Publications (1)

Publication Number Publication Date
JPH05246822A true JPH05246822A (en) 1993-09-24

Family

ID=13837569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8468692A Pending JPH05246822A (en) 1992-03-07 1992-03-07 Antibacterial agent

Country Status (1)

Country Link
JP (1) JPH05246822A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533107A (en) * 2002-07-01 2005-11-04 ファスゲン,エルエルシー. NOVEL COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND METHOD OF USING THE SAME
GB2486804A (en) * 2010-12-22 2012-06-27 Evocutis Plc Antibacterial containing usnic acid/usnate and bismuth or copper salts
CN102949298A (en) * 2011-12-20 2013-03-06 上海莱博生物科技有限公司 Application of usnic acid and/or salts thereof
JP2015514740A (en) * 2012-04-18 2015-05-21 サントレ ナスィヨナル ドゥ ラ ルシェルシュ スィヤンティフィック−セエヌエールエス Liquesteric acid and its derivatives as pigmentation inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533107A (en) * 2002-07-01 2005-11-04 ファスゲン,エルエルシー. NOVEL COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND METHOD OF USING THE SAME
GB2486804A (en) * 2010-12-22 2012-06-27 Evocutis Plc Antibacterial containing usnic acid/usnate and bismuth or copper salts
CN102949298A (en) * 2011-12-20 2013-03-06 上海莱博生物科技有限公司 Application of usnic acid and/or salts thereof
JP2015514740A (en) * 2012-04-18 2015-05-21 サントレ ナスィヨナル ドゥ ラ ルシェルシュ スィヤンティフィック−セエヌエールエス Liquesteric acid and its derivatives as pigmentation inhibitors

Similar Documents

Publication Publication Date Title
DE69833131T2 (en) METAL / THIOL-CONTAINING BIOCIDES
CA2850908C (en) Aqueous antimicrobial composition containing coniferous resin acids
CA2263473C (en) Silver-based antimicrobial compositions
EP0382066A3 (en) Use of dihydroliponic acid as an analgetic, antiphlogistic and/or cytoprotective agent
JP2002526407A5 (en)
DE60017133T2 (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
KR950000142A (en) Use of hydroxy acid-containing L-carnitine esters and acyl L-carnitine esters for the preparation of pharmaceutical compositions for the treatment of skin diseases
US4132781A (en) Method for treatment of acne
JPH05246822A (en) Antibacterial agent
BE885605A (en) BENZO (IJ) QUINOLIZINE-CARBOXYLIC-2 ACID DERIVATIVES USEFUL IN PARTICULAR AS ANTIMICROBIAL DRUGS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS AND PHARMACEUTICAL FORMS CONTAINING THEM
DE69914957T2 (en) NON-SOLID TOPICALLY APPLICABLE PRODUCT CONTAINING GLYZEROL AND ALCHEMILLA VULGARIS EXTRACT
JP2019178170A (en) Use of patchouli extract in preparation of compositions with anti-microorganism effect
DE69801820T2 (en) Use of dichlorobenzyl alcohol to make a composition for topical treatment of inflammation
WO2000050019A2 (en) USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO TREAT DISEASES IN HUMANS AND ANIMALS, WHEREBY SAID DISEASES CAN BE THERAPEUTICALLY INFLUENCED BY INHIBITING THE ACTIVATION OF NF-λB
DE3443985A1 (en) Pharmaceutical preparations against mycotic and bacterial infections, which contain active ingredients which release zinc in ionised form
DE60011432T2 (en) HERBAL COMPOSITIONS FOR JUCKREIZ OR INFECTED SKINS
DE68915154T2 (en) APPLICATION OF AGENTS ACTIVE AGAINST RETROVIRUS AND PRODUCTS OBTAINED THEREFORE.
EP0403575B1 (en) Acyl carnitine for the treatment and prevention of virus infections
JPH05246876A (en) Antibacterial agent
CN114096229A (en) Use of dianhydrohexitols for eliminating the effects of acne, dandruff and off-flavours on cosmetic instruments
CN115487226B (en) External natural bactericide pharmaceutical composition
DE69310565T2 (en) Use of bilobalid and its derivatives for the treatment of infections in humans and pharmaceutical composition suitable for such an application
DE102012000416A1 (en) Topical composition, useful for treating wounds, preferably open wounds and ulcers, comprises fusafungine and/or one of its derivative and onion extract
RU1793919C (en) Composition for bronchopneumonia treatment in animals
CN107998071B (en) Method for improving stability of phenytoin silver and phenytoin silver external preparation